Although most cerebral tumours can be diagnosed by the use of conventional histological staining techniques, there remains a substantial proportion in which the diagnosis remains uncertain and other investigations, such as electron microscopy, are necessary. The monoclonal antibody technique' provides reagents that are specific and reproducible, which makes them ideal markers for immunocytochemistry .23 In this study 50 monoclonal antibodies were initially screened on a wide range of normal and neoplastic tissues, using either indirect immunofluorescence or immunoperoxidase techniques.4 Seven of these were selected on the basis of diagnostic potential: binding to neuroectodermally derived tissues, glial cells, neuronal cells, epithelial cells, and cells of lymphoid origin. The antibodies were used as a panel in a prospective study of 164 cranial and spinal tumours in order to establish the consistency of Accepted for publication 4 October 1984 reaction patterns and their diagnostic capability when compared with classical neuropathological techniques.
In certain cases additional antibodies were used to refine diagnosis by achieving fuller characterisation of cells. The main purpose of the study, however, was to evaluate the diagnostic power of a preselected panel of markers when used routinely as an adjunct to conventional histological techniques.
Material and methods

MONOCLONAL ANTIBODIES
The seven antibodies selected for this study are listed in Table 1 together with reference to their origin. FD19 was raised after immunisation of mice with homogenised human cerebellar astrocytoma (grade I), and UJ13A, UJ127.1 1, and UJ181.4 were raised by immunisation of Balb/C mice with human fetal brain. Spleen cells were fused with the mouse myeloma cell line P3-X63-Ag8-653 using polyethylene glycol. The precise specificities of these 165 
Results
The results show that gliomas of all types express the pan-neuroectodermal UJ13A antigen and contain variable amounts of glial fibrillary acidic protein as detected by antibody FD19 ( Table 2 ). The glial fibrillary acidic protein expression is greatest in astrocytomas, with smaller amounts being found in highly malignant gliomas and also in oligodendrogliomas. This is consistent with the findings of van der Meulen et a19 and Velasco et al,'0 who used glial fibrillary acidic protein antiserum. Weak staining by the neuroblastic cell marker UJ181.4 was seen in 5/31 malignant gliomas and 3/6 oligodendrogliomas.
The various categories of glioma cannot, at present, be distinguished by differing antigenic patterns. But this may eventually be possible-for example, by the use of monoclonal antibodies directed against components of myelin found in oligodendrogliomas.
The 10 medulloblastomas tested all expressed glial fibrillary acidic protein and neuroblastic antigen, as recognised by FD19 and UJ181.4 respec-166 group.bmj.com on January 13, 2018 -Published by http://jcp.bmj.com/ Downloaded from Immunohistological diagnosis of central nervous system tumours using a monoclonal antibody panel 167 tively. The pattern of staining was variable in accordance with the degree of glial or neuronal differentiation of individual tumours." Antibody UJ127.11 stained 8/10 medulloblastomas. Central neuroblastomas are rare, but two were encountered in this series: one was situated in the frontal lobe and the other in the nasopharynx (esthesioneuroblastoma). Both lacked glial fibrillary acidic protein and reacted with UJ13A, UJ181.4, and UJ127.11, a pattern similar to that found in a larger series of systemic neuroblastomas.'2 Schwannomas were characterised by a unique and consistent pattern of reactivity with UJ13A, UJ127.11, and A2B5. Antibody UJ127.11 has previously been widely tested and appears to be a neuronal cell marker' so that this interesting binding pattern confirms the neural crest origin of these tumours.
Metastatic carcinomas in the central nervous system bound antibody LE61 in 36/41 cases. Of the five LE61 negative cases, four reacted with the monoclonal antibody AUA18 (a monoclonal antibody binding to adenocarcinomas, which was generated by Dr J Arklie and obtained from Dr W Bodmer towards the end of the study). It has now been shown that a combination of LE61 and AUA1 will detect 98% of cerebral carcinoma metastases (Coakham HB; unpublished observation) . The remaining case bound UJ13A and was presumably of bronchogenic origin. Primary bronchogenic tumours of neuroectodermal origin (oat cell carcinomas) bind UJ13A2 and, in this series, 5/41 intracranial metastatic carcinomas were shown to have this antigenic profile ( Table 2) . It is important to note that all the UJ13A positive metastases also contained cytokeratin, thus excluding the possibility that they were primary brain tumours.
Choroid plexus tumours and metastatic carcinomas both bind the monoclonal antibody LE61, but confusion in diagnosis is unlikely in view of their different clinical and radiological features, although histologically there are similarities between the two tumour types. Two of the three choroid plexus tumours examined were poorly differentiated, however, so that initial diagnoses of malignant ependymoma were considered. This difficulty in diagnosis could easily be resolved with the monoclonal antibodies since ependymomas do not bind LE61 (Table 2) group.bmj.com on January 13, 2018 -Published by http://jcp.bmj.com/ Downloaded from Immunohistological diagnosis of central nervous system tumours using a monoclonal antibody panel 169 germ cell neoplasm or an anaplastic secondary carcinoma (Fig. la) . Binding of antibodies LE61 and AUA1 showed the tumour to be an adenocarcinoma (Fig. lb, c) . This diagnosis was later confirmed by electron microscopy.
Case 2. Small cell nasopharyngeal tumour A 10 year old boy developed symptoms related to a nasopharyngeal mass, a biopsy of which showed a small round cell tumour which could not be further classified by routine histological examination. Binding of antibodies UJ13A, A2, and UJ127.11 excluded lymphoma or germinoma and indicated the tumour to be an olfactory neuroblastoma. Further antibodies, known to react with neuroblastoma cells, also bound to the tumour cells (data not presented). Appropriate neuraxis radiation was given, but the tumour subsequently metastasised into the cerebrospinal fluid, and the same antibodies were used to identify tumour cells in cytospin preparations.
Case 3. Small cell frontal tumour An 11 year old girl presented with a large frontal tumour, which was found histologically to be composed of small round cells of undetermined nature (Fig. 2a) . Positive immunofluorescence with UJ13A and UJ181.4 showed this to be a primary neuroectodermal tumour with neuroblastic differentiation (Fig. 2b) (Fig. 3a) . Uniform immunofluorescence with 2D1 and B1 (Coulter Electronics), however, showed a brain lymphoma of B cell origin (Fig. 3b, c) . Radiotherapy is indicated for brain lymphoma and may sometimes produce gratifying remission. However, the patient's condition and the wishes of the family precluded this. group.bmj.com on January 13, 2018 -Published by http://jcp.bmj.com/ Downloaded from Coakham, Garson, Allan, Harper, Brownell, Kemshead, Lane . : : . surgery and intraoperative smear preparation supported this diagnosis. Histological sections were also suggestive of lymphoma, although atypical features were noted (Fig. 4a) . Immunological testing showed this tumour to be a carcinoma by positive reactivity with LE61 and HMFG1 (Fig. 4b, c) . A scanty infiltrate of leucocytes was shown with 2D1 ( Fig. 4d) . Radiotherapy was not advised in the light of the revised diagnosis.
In addition to this valuable diagnostic information, the study was useful in assessing the specificity of selected reagents: for example, antibody A2B,, originally reported as a neuronal marker,' stained all neuroectodermal tissues whether normal or neoplastic and also stratified squamous epithelium of the upper gastrointestinal tract and 26/41 carcinomas.
Discussion
The application of immunohistological techniques to cerebral tumour diagnosis, using polyclonal antisera against such antigens as glial fibrillary acidic protein, is already well established.'3 The monoclonal antibodies reported here offer specificity and reproducibility together with the ability to distinguish between certain types of primary brain tumour. These antibodies are directed against three categories of antigen: (a) oncofetal, tumour associated antigen By using combinations of antibodies it is possible to characterise tumours according to their antigenic profiles (Fig. 5) 
